We are dedicated to maintaining strong corporate governance standards. We believe that our governance structure supports our ability to achieve our strategic goals and create sustainable value for our shareholders and stakeholders.

Our board of directors is responsible for corporate governance and is ultimately accountable for the group's activities, strategy, risk management and financial performance. Our Chief Executive Officer is responsible for the management of the business …

GSK’s internal control and risk management arrangements, described on pages 112 and 46 to 54, are an integral part of our corporate governance framework. Chief Executive Officer

Unless otherwise stated the share capital disclosed comprises ordinary shares which are indirectly held by GSK plc. The percentage held by class of share is stated where this is less than 100%. Unless otherwise stated, all subsidiary companies have their registered office and are tax resident in their country of incorporation.

GSK’s internal control and risk management arrangements are an integral part of our overall corporate governance framework and are described on pages 51 to 64 and pages 125 and 126 .

Our Board is responsible for the long-term success of GSK and membership includes the Company Chair, two Executive Directors, one non-independent and eight independent Non-Executive Directors.

GSK’s mission of producing products to ‘help people do more, feel better and live longer’ remains at the heart of its values and culture. There is full commitment from the Board as a whole to support the overarching strategy of creating two great companies.

GSK reports formally to shareholders twice a year, when our half-year and full-year results are announced. The CEO and CFO give presentations on the half-year and full-year results in face-to-face meetings with institutional investors, analysts and the media, which are also accessible via web-cast and teleconference.

The FDA (Food and Drug Administration) must approve clinical studies before they can start, and, based on the clinical study data, the FDA must approve medicines and vaccines before they become available to the public. What is GSK’s approach to clinical studies? GSK unites science, technology and talent to get ahead of disease together.

R&D is the core of our innovation The convergence of science and technology is changing discovery and development, allowing us to make advances once thought impossible. We have built one of the world’s largest genetic datasets, giving us an unprecedented level of understanding of the human immune system and end-to-end insight into the underlying biology of disease. This gives us a ...